The US Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated advanced neuroendocrine tumors.

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

The approval came on the bases of the results from the phase 3 CABINET study. The study compared cabozantinib to a placebo in ...

Primary neuroendocrine carcinoma of the male breast is an exceptionally rare entity, with fewer than 50 cases documented in ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Table 2. Proposed Pathology Workup of Neuroendocrine Prostate Cancer on the Basis of the Study by Haffner et al 72 Morphology Classifier (choose one) IHC Classifier (include the status of each marker) ...

In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts caution that more research is needed. Gavin Nielsen was 2 years old when ...

The pituitary gland produces prolactin. It is located at the base of your brain and is part of your body’s neuroendocrine system. Tumors in the pituitary gland can cause elevated levels of prolactin, ...

Ashley Robinson passed "the most insane amount of blood," but doctors said there was "no chance" he had cancer and diagnosed him with hemorrhoids Kennedy News & Media A chef, who was planning his ...

Teddi Mellencamp revealed that more tumors have been found in her brain and lungs. On Thursday, March 6, the Real Housewives of Beverly Hills alum, 43, posted a health update to her Instagram ...